{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:34:20Z","timestamp":1752230060572,"version":"3.41.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver Transpl"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>The recently reported benefit of telbivudine for renal function has not been systematically studied in long\u2010term liver transplantation (LT) recipients who are at high risk for renal impairment. We aimed to examine whether switching lamivudine therapy to telbivudine could improve renal function in LT recipients who have impaired renal function. This single\u2010center, prospective cohort study enrolled LT recipients who were on lamivudine for hepatitis B virus (HBV) prophylaxis and who had renal impairment for at least 1 year. Lamivudine was switched to telbivudine. The primary outcome was to evaluate the change in renal function at weeks 12, 24, 36, and 48. The secondary outcomes were to assess the efficacy of telbivudine for HBV prophylaxis and the safety profile of telbivudine in the posttransplant setting. After 45 patients were enrolled, the study was terminated early because of increased rates of polyneuropathy\/myopathy. During telbivudine treatment (median, 64 weeks), estimated glomerular filtration rate (eGFR) increased in 34 patients (76%). The improvement in renal function was prominent after 24 weeks of telbivudine treatment. Telbivudine was effective as prophylaxis against HBV recurrence. Twenty\u2010six patients (58%) developed polyneuropathy and\/or myopathy. The 1\u2010year estimated incidence of polyneuropathy\/myopathy was 28%. Diabetes was the strongest predictor of polyneuropathy\/myopathy (hazard ratio, 4.13; 95% confidence interval, 1.49\u201011.50;<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.007). In conclusion, although it seems to have a favorable effect in the improvement of renal function and seems to be effective in the prevention of HBV recurrence, the high risk of polyneuropathy and myopathy hampers the use of telbivudine in LT recipients.<jats:italic toggle=\"yes\">Liver Transpl 21:1066\u20101075, 2015<\/jats:italic>. \u00a9 2015 AASLD.<\/jats:p>","DOI":"10.1002\/lt.24131","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T22:06:26Z","timestamp":1428012386000},"page":"1066-1075","source":"Crossref","is-referenced-by-count":8,"title":["Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy"],"prefix":"10.1097","volume":"21","author":[{"given":"Ilker","family":"Turan","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suna","family":"Yapali","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fikret","family":"Bademkiran","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur","family":"Kose","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soner","family":"Duman","sequence":"additional","affiliation":[{"name":"Section of Nephrology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Sozbilen","sequence":"additional","affiliation":[{"name":"Department of Organ Transplantation and Research Center, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulya","family":"Gunsar","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galip","family":"Ersoz","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulus Salih","family":"Akarca","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Ozutemiz","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeki","family":"Karasu","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, School of Medicine,Ege University,Izmir,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2015,6,23]]},"reference":[{"key":"lt24131-bib-0001-20240115","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1440-1746.2006.04782.x","article-title":"Living donor liver transplantation for hepatitis B cirrhosis","volume":"22","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"lt24131-bib-0003-20240115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long\u2010term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","year":"2013","journal-title":"Liver Transpl"},{"key":"lt24131-bib-0004-20240115","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1478-3231.2009.02085.x","article-title":"Current management of hepatitis B virus infection before and after liver transplantation","volume":"29","year":"2009","journal-title":"Liver Int"},{"issue":"suppl 1","key":"lt24131-bib-0005-20240115","first-page":"55","article-title":"Management of hepatitis B in liver transplantation patients","volume":"24","year":"2004","journal-title":"Semin Liver Dis"},{"key":"lt24131-bib-0006-20240115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","year":"2013","journal-title":"Liver Transpl"},{"key":"lt24131-bib-0007-20240115","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","year":"2011","journal-title":"Gastroenterology"},{"key":"lt24131-bib-0008-20240115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1\u2010year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"129","year":"2005","journal-title":"Gastroenterology"},{"key":"lt24131-bib-0009-20240115","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"lt24131-bib-0010-20240115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2\u2010year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"lt24131-bib-0011-20240115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double\u2010blind trial","volume":"47","year":"2008","journal-title":"Hepatology"},{"key":"lt24131-bib-0012-20240115","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment\u2010naive patients with HBV\u2010related decompensated cirrhosis","volume":"19","year":"2012","journal-title":"J Viral Hepat"},{"key":"lt24131-bib-0013-20240115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1743-422X-7-211","article-title":"Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review","volume":"7","year":"2010","journal-title":"Virol J"},{"key":"lt24131-bib-0014-20240115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10096-012-1723-6","article-title":"Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta\u2010analysis","volume":"32","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"lt24131-bib-0015-20240115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","article-title":"Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"lt24131-bib-0016-20240115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/14740338.2010.507190","article-title":"Safety evaluation of telbivudine","volume":"9","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"suppl","key":"lt24131-bib-0017-20240115","first-page":"S185","article-title":"Side effects of long\u2010term oral antiviral therapy for hepatitis B","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"lt24131-bib-0018-20240115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11901-010-0039-1","article-title":"A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B","volume":"9","year":"2010","journal-title":"Curr Hepat Rep"},{"key":"lt24131-bib-0019-20240115","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2893.2010.01412.x","article-title":"Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"issue":"suppl 1","key":"lt24131-bib-0020-20240115","first-page":"655A","article-title":"Creatine kinase (CK) elevations and muscle toxicities associated with chronic telbivudine (LDT) use in prospective clinical trials [abstract]","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"lt24131-bib-0021-20240115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","article-title":"Telbivudine plus pegylated interferon alfa\u20102a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"lt24131-bib-0022-20240115","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.transproceed.2014.07.058","article-title":"Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function","volume":"46","year":"2014","journal-title":"Transplant Proc"},{"key":"lt24131-bib-0023-20240115","first-page":"129","article-title":"Efficacy and safety of telbivudine in patients after OLT: a single\u2010center clinical experience","volume":"5","year":"2011","journal-title":"Hepatol Int"},{"journal-title":"J Viral Hepat","article-title":"Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease","year":"2014","key":"lt24131-bib-0024-20240115"},{"key":"lt24131-bib-0025-20240115","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","article-title":"End\u2010stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin\u2010based immunotherapy: risk of development and treatment","volume":"72","year":"2001","journal-title":"Transplantation"},{"key":"lt24131-bib-0026-20240115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"lt24131-bib-0027-20240115","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post\u2010liver transplant: results of the NIDDK long\u2010term follow\u2010up study","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"lt24131-bib-0028-20240115","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2010.12.001","article-title":"Immunosuppression in liver transplant recipients with renal impairment","volume":"54","year":"2011","journal-title":"J Hepatol"},{"key":"lt24131-bib-0029-20240115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"lt24131-bib-0031-20240115","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"lt24131-bib-0032-20240115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1212\/01.WNL.0000149522.32823.EA","article-title":"Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"64","year":"2005","journal-title":"Neurology"},{"key":"lt24131-bib-0033-20240115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"issue":"suppl","key":"lt24131-bib-0034-20240115","first-page":"401A","article-title":"Consistent renal function improvement with telbivudine treatment in combination with adefovir or tenofovir [abstract]","volume":"56","year":"2012","journal-title":"Hepatology"},{"issue":"suppl","key":"lt24131-bib-0035-20240115","first-page":"679A","article-title":"Renal function improvement with telbivudine but not lamivudine in patients with chronic hepatitis B (CHB) and severe fibrosis or cirrhosis [abstract]","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"lt24131-bib-0036-20240115","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/S0168-8278(13)60747-3","article-title":"eGFR improvement in chronic hepatitis B patients with telbivudine treatment is independent of antiviral activity","volume":"58","year":"2013","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"lt24131-bib-0037-20240115","first-page":"S225","article-title":"Assessing renal function in compensated chronic hepatitis B patients with diabetes treated with telbivudine versus other therapies","volume":"7","year":"2013","journal-title":"Hepatol Int"},{"issue":"suppl 1","key":"lt24131-bib-0038-20240115","first-page":"S181","article-title":"Beneficial effect of telbivudine on renal function in hepatoma patients receiving combination chemotherapy","volume":"7","year":"2013","journal-title":"Hepatol Int"},{"key":"lt24131-bib-0039-20240115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1478-3231.2011.02490.x","article-title":"Efficacy and safety of prolonged 3\u2010year telbivudine treatment in patients with chronic hepatitis B","volume":"31","year":"2011","journal-title":"Liver Int"},{"key":"lt24131-bib-0040-20240115","first-page":"e37","article-title":"Efficacy and safety of continuous 4\u2010year telbivudine treatment in patients with chronic hepatitis B","volume":"20","year":"2013","journal-title":"J Viral Hepat"},{"issue":"suppl","key":"lt24131-bib-0041-20240115","first-page":"S329","article-title":"Increased risk with combination of telbivudine and pegylated\u2010interferon Alfa\u20102A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"lt24131-bib-0042-20240115","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","article-title":"Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes","volume":"51","year":"2002","journal-title":"Diabetes"},{"key":"lt24131-bib-0043-20240115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tins.2013.04.008","article-title":"Novel pathogenic pathways in diabetic neuropathy","volume":"36","year":"2013","journal-title":"Trends Neurosci"},{"key":"lt24131-bib-0044-20240115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/jclinpath-2013-202069","article-title":"Lamivudine\/telbivudine\u2010associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion","volume":"67","year":"2014","journal-title":"J Clin Pathol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.24131","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.24131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201508000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:11:58Z","timestamp":1747861918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201508000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,23]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.24131","relation":{},"ISSN":["1527-6465","1527-6473"],"issn-type":[{"type":"print","value":"1527-6465"},{"type":"electronic","value":"1527-6473"}],"subject":[],"published":{"date-parts":[[2015,6,23]]}}}